2024 Revenues ($USD) : $12.74B

CSL Limited clocked in total revenue of $22.2 billion for its fiscal year ending June 30, 2024. Under CEO Dr. Paul McKenzie, the company funnelled $1.43 billion, or about 9.6% of that revenue, into research and development during the period. Early signs from its half-year results ending December 31, 2024, pointed towards continued growth, and CSL expects to keep its R&D spending hovering around the 10% mark for its 2025 fiscal year. (Just a reminder, CSL runs its business through units like CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor).

Looking at recent news, CSL Behring snagged Swiss approval in February 2025 for its ANDEMBRY (garadacimab), aimed at preventing attacks in hereditary angioedema (HAE) patients 12 and up. This marked its fifth regulatory green light for what's being called the first once-monthly Factor XIIa inhibitor for this condition.

Also in February, CSL shared some positive long-term data for its gene therapy HEMGENIX (etranacogene dezaparvovec-drlb). Four years after infusion, adults with hemophilia B showed sustained benefit, with most (94%) staying off regular Factor IX shots.

Back in October 2024, CSL Vifor, alongside partner Travere Therapeutics, got Swiss approval for FILSPARI (sparsentan) to treat IgA nephropathy (IgAN). And on a different note, CSL Seqirus flagged in April 2025 that lab-confirmed flu cases in Australia hit record levels for the first quarter.